Zhu Yingqian, Geng Shasha, Li Qingqing, Jiang Hua
Department of Geriatrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Department of General Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Front Bioeng Biotechnol. 2020 Nov 5;8:557652. doi: 10.3389/fbioe.2020.557652. eCollection 2020.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative pathogen for coronavirus disease-2019 (COVID-19), which has posed an increasing serious public health threat. However, still there are no approved antiviral agents or vaccines available yet. Mesenchymal stem cells (MSCs) are emerging as a novel promising adjuvant therapy for the attenuation of COVID-19 based on its putative pathogenesis. MSCs may exert anti-inflammatory, immunomodulatory, anti-apoptotic, as well as regenerative effects through a series of mechanisms. Remarkably, MSCs may be resistant to virus infection, which is fundamental for the treatment of COVID-19. The beneficial therapeutic effects of MSCs have been preliminarily proved to be safe and efficacious for the treatment of COVID-19 in current clinical trials. This work aims to review the beneficial effects of MSCs in treating ALI/ARDS, which provides novel insight into the potential therapeutic strategies against COVID-19. However, further research is warranted regarding both safety and efficacy of MSCs.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是2019冠状病毒病（COVID-19）的致病病原体，对公众健康构成了日益严重的威胁。然而，目前仍没有获批的抗病毒药物或疫苗。基于其假定的发病机制，间充质干细胞（MSCs）正作为一种有前景的新型辅助疗法用于减轻COVID-19的症状。MSCs可能通过一系列机制发挥抗炎、免疫调节、抗凋亡以及再生作用。值得注意的是，MSCs可能对病毒感染具有抗性，这对于COVID-19的治疗至关重要。在当前的临床试验中，MSCs的有益治疗效果已初步证明对治疗COVID-19是安全有效的。这项工作旨在综述MSCs在治疗急性肺损伤/急性呼吸窘迫综合征（ALI/ARDS）中的有益作用，这为对抗COVID-19的潜在治疗策略提供了新的见解。然而，关于MSCs的安全性和有效性仍需进一步研究。
